Iterum Therapeutics (ITRM) Operating Income (2017 - 2022)
Historic Operating Income for Iterum Therapeutics (ITRM) over the last 6 years, with Q4 2022 value amounting to -$7.9 million.
- Iterum Therapeutics' Operating Income fell 1606.38% to -$7.9 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$30.4 million, marking a year-over-year decrease of 2382.52%. This contributed to the annual value of -$18.7 million for FY2024, which is 6061.35% up from last year.
- According to the latest figures from Q4 2022, Iterum Therapeutics' Operating Income is -$7.9 million, which was down 1606.38% from -$7.0 million recorded in Q3 2022.
- Over the past 5 years, Iterum Therapeutics' Operating Income peaked at -$4.6 million during Q4 2020, and registered a low of -$31.0 million during Q3 2019.
- Its 5-year average for Operating Income is -$13.3 million, with a median of -$8.2 million in 2020.
- Per our database at Business Quant, Iterum Therapeutics' Operating Income plummeted by 20118.13% in 2018 and then skyrocketed by 7996.38% in 2020.
- Quarter analysis of 5 years shows Iterum Therapeutics' Operating Income stood at -$23.9 million in 2018, then increased by 3.2% to -$23.2 million in 2019, then skyrocketed by 79.96% to -$4.6 million in 2020, then crashed by 47.05% to -$6.8 million in 2021, then decreased by 16.06% to -$7.9 million in 2022.
- Its Operating Income was -$7.9 million in Q4 2022, compared to -$7.0 million in Q3 2022 and -$8.0 million in Q2 2022.